SWHR Input to ICER on Assessment of New Alzheimer’s Disease Treatment

Policy Engagement

Published 10/16/20

SWHR provided open input to the Institute for Clinical and Economic Review (ICER) on contextual considerations surrounding Alzheimer’s disease (AD) and its treatment from a women’s health perspective.

ICER recently initiated a new topic review of AD to assess the comparative clinical effectiveness and value of aducanumab, a new AD treatment slated for review by the Food and Drug Administration in early 2021.

Last year, SWHR conceived a set of principles to help ensure value frameworks and assessments account for patient population diversity and have the infrastructure and analytic capability to evaluate data that matters to women. Grounded by these principles, SWHR encouraged ICER to:

  • Carefully consider the role of sex and gender differences in regards to AD etiology, symptom presentation, and disease course in ICER’s AD research protocol;
  • Strive to account for these topics and their impact on women in ICER’s AD model analysis plan;
  • Consider all available evidence-based AD treatment options within the health care system including behavioral therapies and lifestyle interventions;
  • Capture what matters most to AD patients, caregivers, and society by quantitatively accounting for the public health burden in ICER cost-effectiveness methodologies. This includes AD burden of illness factors such as caregiver burden that impact women disproportionately.

Read SWHR’s Comments